US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore ...
French drugmaker Ipsen (Euronext: IPN) announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback